Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.

Tewari KS.

J Gynecol Oncol. 2019 Nov;30(6):e119. doi: 10.3802/jgo.2019.30.e119. No abstract available.

2.

Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results.

Tewari KS.

J Clin Oncol. 2019 Sep 27:JCO1902024. doi: 10.1200/JCO.19.02024. [Epub ahead of print] No abstract available.

PMID:
31560582
3.

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.

Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA.

Gynecol Oncol. 2019 Oct;155(1):69-74. doi: 10.1016/j.ygyno.2019.07.020. Epub 2019 Aug 10.

PMID:
31409486
4.

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.

Tewari KS, Monk BJ.

J Clin Oncol. 2019 Sep 20;37(27):2472-2489. doi: 10.1200/JCO.18.02303. Epub 2019 Aug 12. No abstract available.

PMID:
31403858
5.

Cervical cancer in Tanzania: A systematic review of current challenges in six domains.

Runge AS, Bernstein ME, Lucas AN, Tewari KS.

Gynecol Oncol Rep. 2019 May 21;29:40-47. doi: 10.1016/j.gore.2019.05.008. eCollection 2019 Aug. Review.

6.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.

PMID:
31216226
7.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O'Malley DM, Spirtos NM, Small W Jr, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS.

N Engl J Med. 2019 Jun 13;380(24):2317-2326. doi: 10.1056/NEJMoa1813181.

PMID:
31189035
8.

Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.

Tewari KS.

J Clin Oncol. 2019 Jun 10;37(17):1449-1454. doi: 10.1200/JCO.19.00119. Epub 2019 Apr 26.

PMID:
31026210
9.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS.

J Clin Oncol. 2019 Jun 1;37(16):1380-1390. doi: 10.1200/JCO.18.01568. Epub 2019 Apr 19. Erratum in: J Clin Oncol. 2019 Sep 1;37(25):2299.

PMID:
31002578
10.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum in: Obstet Gynecol. 2019 Apr;133(4):830.

PMID:
30633128
11.

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations.

Liu MC, Tewari KS.

Drugs Context. 2018 Dec 27;7:212558. doi: 10.7573/dic.212558. eCollection 2018. Review.

12.

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.

Pearre DC, Tewari KS.

Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018. Review.

13.

Chemical approaches for the enhancement of 5-aminolevulinic acid-based photodynamic therapy and photodiagnosis.

Tewari KM, Eggleston IM.

Photochem Photobiol Sci. 2018 Nov 1;17(11):1553-1572. doi: 10.1039/c8pp00362a. Epub 2018 Oct 17. Review.

PMID:
30328459
14.

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS.

J Clin Oncol. 2018 Oct 5:JCO1800454. doi: 10.1200/JCO.18.00454. [Epub ahead of print]

PMID:
30289732
15.

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA.

Gynecol Oncol. 2018 Nov;151(2):257-263. doi: 10.1016/j.ygyno.2018.08.027. Epub 2018 Aug 31.

PMID:
30177462
16.

Bevacizumab in Cervical Cancer: 5 Years After.

Pfaendler KS, Liu MC, Tewari KS.

Cancer J. 2018 Jul/Aug;24(4):187-192. doi: 10.1097/PPO.0000000000000324. Review.

PMID:
30119082
17.

Catalytic activity of nickel nanoparticles stabilized by adsorbing polymers for enhanced carbon sequestration.

Seo S, Perez GA, Tewari K, Comas X, Kim M.

Sci Rep. 2018 Aug 6;8(1):11786. doi: 10.1038/s41598-018-29605-1.

19.

Molecular cloning and functional analysis of the promoter of γ-Tocopherol Methyl Transferase (γ-TMT) gene of soybean (Glycine max).

Tewari K, Kumar V, Kumar A, Bansal N, Vinutha T, Ali K, Sachdev A, Kumari S, Dahuja A.

3 Biotech. 2018 Aug;8(8):325. doi: 10.1007/s13205-018-1347-3. Epub 2018 Jul 17.

20.

Oncofertility in the setting of advanced cervical cancer - A case report.

Gordon C, Carmichael JC, Tewari KS.

Gynecol Oncol Rep. 2018 Mar 2;24:27-29. doi: 10.1016/j.gore.2018.03.001. eCollection 2018 May.

21.

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA.

Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24.

22.

Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.

Minion LE, Tewari KS.

Gynecol Oncol. 2018 Mar;148(3):609-621. doi: 10.1016/j.ygyno.2018.01.009. Epub 2018 Feb 3. Review.

23.

Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.

Longoria TC, Tewari KS.

Expert Opin Drug Metab Toxicol. 2018 May;14(5):543-550. doi: 10.1080/17425255.2018.1461838. Epub 2018 May 16. Review.

PMID:
29620474
24.

A novel homozygous mutation in POLR3A gene causing 4H syndrome: a case report.

Tewari VV, Mehta R, Sreedhar CM, Tewari K, Mohammad A, Gupta N, Gulati S, Kabra M.

BMC Pediatr. 2018 Apr 4;18(1):126. doi: 10.1186/s12887-018-1108-9.

25.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA.

Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.

PMID:
29550184
26.

Clinical and Hematological Profile of Patients with Dengue Fever at a Tertiary Care Hospital - An Observational Study.

Tewari K, Tewari VV, Mehta R.

Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018021. doi: 10.4084/MJHID.2018.021. eCollection 2018.

27.

Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.

Wolford JE, Tewari KS.

Expert Opin Drug Discov. 2018 May;13(5):445-457. doi: 10.1080/17460441.2018.1443074. Epub 2018 Feb 26. Review.

28.

Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.

Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J.

Gynecol Oncol Res Pract. 2018 Jan 5;5:1. doi: 10.1186/s40661-017-0058-5. eCollection 2018. Review.

29.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.

Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.

30.

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.

Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS.

Br J Cancer. 2018 Jan;118(2):162-170. doi: 10.1038/bjc.2017.400. Epub 2017 Nov 28.

31.

Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA.

Gynecol Oncol. 2018 Jan;148(1):49-55. doi: 10.1016/j.ygyno.2017.10.011. Epub 2017 Nov 23.

32.

The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.

Serna-Gallegos TR, La-Fargue CJ, Tewari KS.

Recent Pat Biotechnol. 2018;12(2):101-112. doi: 10.2174/1872208311666171122152131. Review.

PMID:
29173192
33.

Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ; Ovarian Cancer Association Consortium, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.

34.

Molecular cloning, heterologous expression and functional characterization of gamma tocopherol methyl transferase (γ-TMT) from Glycine max.

Tewari K, Dahuja A, Sachdev A, Kumar V, Ali K, Kumar A, Kumari S.

Protein Expr Purif. 2017 Dec;140:81-89. doi: 10.1016/j.pep.2017.08.006. Epub 2017 Aug 12.

PMID:
28811265
35.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

36.

Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology.

Wolford JE, Tewari KS.

J Gynecol Oncol. 2017 Sep;28(5):e74. doi: 10.3802/jgo.2017.28.e74. No abstract available.

37.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

38.

Endolysosomal targeting of a clinical chlorin photosensitiser for light-triggered delivery of nano-sized medicines.

Yaghini E, Dondi R, Tewari KM, Loizidou M, Eggleston IM, MacRobert AJ.

Sci Rep. 2017 Jul 20;7(1):6059. doi: 10.1038/s41598-017-06109-y.

39.

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Chafe W, Monk BJ, Aghajanian C.

Gynecol Oncol. 2017 Sep;146(3):554-559. doi: 10.1016/j.ygyno.2017.05.033. Epub 2017 Jul 18.

40.

Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies.

Tewari KS.

Gynecol Oncol Res Pract. 2016 Oct 24;3:10. doi: 10.1186/s40661-016-0031-8. eCollection 2016.

41.

High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK.

Gynecol Oncol. 2017 Aug;146(2):247-253. doi: 10.1016/j.ygyno.2017.05.017. Epub 2017 May 19.

42.

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS.

Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21.

43.

Identification of the fatty acid activation site on human ClC-2.

Cuppoletti J, Tewari KP, Chakrabarti J, Malinowska DH.

Am J Physiol Cell Physiol. 2017 Jun 1;312(6):C707-C723. doi: 10.1152/ajpcell.00267.2016. Epub 2017 Apr 19.

44.

Flexible synthesis of cationic peptide-porphyrin derivatives for light-triggered drug delivery and photodynamic therapy.

Dondi R, Yaghini E, Tewari KM, Wang L, Giuntini F, Loizidou M, MacRobert AJ, Eggleston IM.

Org Biomol Chem. 2016 Dec 7;14(48):11488-11501.

45.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

46.
47.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB.

Gynecol Oncol. 2016 Nov;143(2):294-301. doi: 10.1016/j.ygyno.2016.08.317. Epub 2016 Aug 17.

48.

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.

Minion LE, Tewari KS.

Expert Rev Anticancer Ther. 2017 Mar;17(3):191-198. doi: 10.1080/14737140.2016.1246187. Epub 2017 Feb 15. Review.

49.

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.

Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL.

Gynecol Oncol. 2016 Dec;143(3):460-465. doi: 10.1016/j.ygyno.2016.10.016. Epub 2016 Oct 12.

50.

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.

Supplemental Content

Loading ...
Support Center